Increased prevalence of heterozygous 21‐OH germline mutations in patients with adrenal incidentalomas
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Summary: objective As a result of the widespread use and the enhanced quality of high‐resolution radiological techniques [computed tomography (CT), magnetic resonance imaging (MRI)] a high frequency (4–10%) of adrenal incidentalomas has been detected in the general population. It is still debated whether undiagnosed 21‐hydroxylase (21‐OH) deficiency, accounting for more than 90% of congenital adrenal hyperplasia (CAH) cases, predisposes for adrenal tumours. We therefore performed an analysis of the prevalence of 21‐OH germline mutations in patients with non‐functional adrenal incidentalomas. subjects and methods Fifty Austrian patients with non‐functional adrenal adenomas detected by CT for unrelated reasons were screened by PCR‐based sequencing for the most common point mutations and by Southern blot analysis for large gene deletion/conversion events of the 21‐OH gene. results Heterozygosity for large gene conversions was shown in 5 (10%), for Q318 point mutations in 2 (4%) and for the Intron2splice mutation in 1 (2%) of the 50 patients with adrenal adenomas. One (2%) patient (70 years of age), identified to have a chimeric CYP21AB gene with a junction site before Intron 2 on one and a large (30 kb) deletion on the other allele, was diagnosed to be affected by CAH. conclusion 21‐OH mutation screening indicates a higher frequency of classic CAH carriers (16%) and of manifest CAH (2%) due to 21‐OH‐deficiency among patients with adrenal adenomas than in the general population (1–2% carrier frequency for classic CAH).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
Congenital adrenal hyperplasia
Speiser, P. W., & White, P. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021561 · Cited by 1,405
Structure of human steroid 21-hydroxylase genes.
White, P. C., New, M. I., & Dupont, B. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.14.5111 · Cited by 569
MANAGEMENT APPROACHES TO ADRENAL INCIDENTALOMAS
Young, W. F. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70122-5 · Cited by 415
Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia.
Jaresch, S., Kornely, E., Kley, H. K., & Schlaghecke, R. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.74.3.1311000 · Cited by 227 · cited 2×
“OH deficiency may be by chance rather than due to a common pathomechanism, although the higher prevalence of adrenal tumours in CAH is a welldescribed phenomenon (Jaresch et al., 1992; White & Speiser, 2000).”
BackgroundBlanchong, C. A., Zhou, B., Rupert, K. L., Chung, E. K., Jones, K. N., Sotos, J. F., Zipf, W. B., Rennebohm, R. M., & Yu, C. Y. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.12.2183 · Cited by 187 · cited 4×
“Recent findings (Blanchong et al., 2000) of a significant difference of modular arrangements of RCCX, a genetic unit composed of nuclear protein kinase RP, CYP21, complement © 2002 Blackwell Science Ltd, Clinical Endocrinology, 56, 811–816 C4 and tenascin (TNX) support this hypothesis and encourage…”
BackgroundInfluentiall'Allemand, D. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.12.4562 · Cited by 90 · cited 5×
“1) with a junction site before intron 2 (thus exclusively affecting the promotor region and the Pro30Leu locus), however, has only recently been characterized fully (L’Àllemand et al., 2000) and shown to account for a considerable amount of Pro30Leu aberrations (Baumgartner-Parzer et al., 2001).”
BackgroundInfluentialBaumgartner-Parzer, S. M., Schulze, E., Waldhäusl, W., Pauschenwein, S., Rondot, S., Nowotny, P., Meyer, K., Frisch, H., Waldhauser, F., & Vierhapper, H. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.10.7898 · Cited by 74 · cited 5×
“…defects than those described in the present study may escape identification unless Southern blot analysis, which is no longer used routinely (White & Speiser, 2000), or specific PCR and sequence analyses are employed (Koppens et al., 1992; Schulze et al., 1995; Baumgartner-Parzer et al., 2001).”
BackgroundMethodSelf-citation
Cited by
Congenital adrenal hyperplasia.
Merke, D. P., & Bornstein, S. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66736-0 · Cited by 628
Forest, M. G. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh047 · Cited by 200
Molecular genetics of adrenocortical tumours, from familial to sporadic diseases
Libé, R., & Bertherat, J. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02004 · Cited by 168
Falhammar, H., & Nordenström, A. (2015) · Endocrine · doi:10.1007/s12020-015-0656-0 · Cited by 127
Clinical outcomes in the management of congenital adrenal hyperplasia
Falhammar, H., & Thorén, M. (2012) · Endocrine · doi:10.1007/s12020-011-9591-x · Cited by 106
Metadata
- Authors
- Baumgartner‐Parzer, S. M., Pauschenwein, S., Waldhäusl, W., Pölzler, K., Nowotny, P., & Vierhapper, H.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2002-06
- Volume
- 56
- Issue
- 6
- Pages
- 811-816
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W1999072432
- Cited by
- 32
- References
- 8
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased prevalence of heterozygous 21‐OH germline mutations in patients with adrenal incidentalomas. https://app.cochat.ai/papers/10.1046/j.1365-2265.2002.01299.x
- The paper
- Baumgartner‐Parzer, S. M., Pauschenwein, S., Waldhäusl, W., Pölzler, K., Nowotny, P., & Vierhapper, H. (2002). Increased prevalence of heterozygous 21‐OH germline mutations in patients with adrenal incidentalomas. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2002.01299.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.